FibroBiologics faces Nasdaq delisting over $1 bid

FibroBiologics, Inc. reports that Nasdaq’s Listing Qualifications staff issued a Staff Determination on July 22, 2026 to delist its securities from The Nasdaq Capital Market.

Rhea-AI Filing Summary

FibroBiologics, Inc. reports that Nasdaq’s Listing Qualifications staff issued a Staff Determination on July 22, 2026 to delist its securities from The Nasdaq Capital Market. The notice cites noncompliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

The company’s bid price closed below $1.00 for 30 consecutive business days from June 8 through July 21, 2026. Because FibroBiologics effected a reverse stock split within the prior year, it is not eligible for the usual 180-day cure period under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Unless it requests an appeal by July 29, 2026, trading is expected to be suspended at the opening of business on July 31, 2026. FibroBiologics intends to timely request a hearing before a Nasdaq Hearings Panel, which will stay delisting actions during the hearing process, but there is no assurance the appeal or any plan to regain compliance will succeed.

Positive

• None.

Negative

• Nasdaq issued a Staff Determination to delist FibroBiologics after its bid price stayed below $1.00 for 30 consecutive business days, with no 180-day cure period available due to a recent reverse stock split.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum Bid Price Requirement: $1.00 per share Noncompliance Period: 30 consecutive business days Staff Determination Date: July 22, 2026 +2 more

5 metrics

Minimum Bid Price Requirement $1.00 per share Required under Nasdaq Listing Rule 5550(a)(2) for continued listing

Noncompliance Period 30 consecutive business days Bid price closed below $1.00 from June 8 through July 21, 2026

Staff Determination Date July 22, 2026 Date Nasdaq Listing Qualifications staff issued delisting determination

Appeal Request Deadline July 29, 2026 Latest date to request a hearing before a Nasdaq Hearings Panel

Scheduled Suspension Date July 31, 2026 Date securities would be suspended at market open absent an appeal

Key Terms

Nasdaq Listing Rule 5550(a)(2), Bid Price Rule, reverse stock split, Nasdaq Hearings Panel, +1 more

5 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"not in compliance with Nasdaq Listing Rule 5550(a)(2)"

Bid Price Rule regulatory

"which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”)"

reverse stock split financial

"not eligible for any such compliance period... due to the fact that the Company has effected a reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

Nasdaq Hearings Panel regulatory

"request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

Staff Determination regulatory

"received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department"

A staff determination is a formal decision or finding made by agency or company employees who handle reviews and enforcement, rather than by higher-level boards or executives. Think of it like a referee’s ruling during a game: it resolves a specific procedural or compliance question and can affect whether a filing, claim, or product moves forward, the timing of approvals, and potential legal or market consequences for investors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What triggered Nasdaq’s delisting notice for FibroBiologics (FBLG)?

Nasdaq staff moved to delist FibroBiologics after its bid price stayed below $1.00 per share for 30 consecutive business days, from June 8 through July 21, 2026, violating Nasdaq Listing Rule 5550(a)(2) on minimum bid price.

Why doesn’t FibroBiologics (FBLG) get a 180-day cure period from Nasdaq?

FibroBiologics is not eligible for the usual 180-day cure period because it effected a reverse stock split within the prior year, as referenced under Nasdaq Listing Rule 5810(c)(3)(A)(iv) governing minimum bid price deficiencies.

What deadlines does FibroBiologics (FBLG) face regarding Nasdaq delisting?

FibroBiologics must request an appeal by July 29, 2026, or its securities are scheduled to be suspended and delisted from The Nasdaq Capital Market at the opening of business on July 31, 2026, according to Nasdaq staff.

How does FibroBiologics (FBLG) plan to respond to Nasdaq’s delisting action?

FibroBiologics intends to timely request a hearing before a Nasdaq Hearings Panel, present a plan to regain compliance, and monitor its closing bid price while evaluating options to address the Bid Price Rule deficiency.

Does a hearing guarantee FibroBiologics (FBLG) will stay listed on Nasdaq?

No. A timely hearing request will temporarily stay delisting actions during the process, but the company states there can be no assurance the Panel will grant continued listing or that it can regain or maintain compliance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 04:05 PM Accepted by SEC EDGAR 07/24/2026 - 04:05 PM Learn about SEC filing dates

false000195877700019587772026-07-222026-07-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2026

FibroBiologics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41934	86-3329066
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
9350 Kirby Drive, Suite 300
Houston, Texas				77054
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 281 671-5150

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value		FBLG		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 22, 2026, FibroBiologics, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq Staff had determined to delist the Company’s securities from The Nasdaq Capital Market.

The Staff Determination stated that the bid price of the Company’s listed securities had closed at less than $1.00 per share over the previous 30 consecutive business days, from June 8, 2026 through July 21, 2026, and that, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”). The Staff Determination further stated that, although companies are normally afforded a 180-calendar day period to demonstrate compliance with the Bid Price Rule, the Company is not eligible for any such compliance period pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to the fact that the Company has effected a reverse stock split over the prior one-year period.

Unless the Company requests an appeal of this determination by July 29, 2026, Nasdaq staff has determined that the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on July 31, 2026.

The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal Nasdaq Staff’s determination. A timely hearing request will stay any further delisting actions through the hearing process. At the hearing, the Company expects to present its plan to regain compliance with Nasdaq’s continued listing requirements. There can be no assurance that the Company will be successful in its appeal, that the Panel will grant the Company’s request for continued listing, or that the Company will be able to regain or maintain compliance with any applicable Nasdaq listing requirements.

The Company intends to actively monitor the closing bid price of its common stock and evaluate all available options to regain compliance with the Bid Price Rule.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FibroBiologics, Inc.
Date:	July 24, 2026	By:	/s/ Pete O'Heeron
			Name: Pete O'Heeron Title: Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.3 KB